Iovance Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 05, 2021 at 05:19 pm EDT
Share
Iovance Biotherapeutics, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 81.426 million compared to USD 63.627 million a year ago. Net loss was USD 81.351 million compared to USD 63.018 million a year ago. Basic loss per share from continuing operations was USD 0.53 compared to USD 0.47 a year ago. For the half year, operating loss was USD 156.996 million compared to USD 134.437 million a year ago. Net loss was USD 156.800 million compared to USD 132.613 million a year ago. Basic loss per share from continuing operations was USD 1.04 compared to USD 1.02 a year ago.
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
IOVANCE BIOTHERAPEUTICS, INC. 
